Prestige Wealth Management Group’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-65
Closed -$790 – 1031
2025
Q3
$790 Hold
65
– – ﹤0.01% 888
2025
Q2
$1.21K Buy
65
+2
+3% +$40 ﹤0.01% 828
2025
Q1
$1.21K Buy
63
+35
+125% +$1.02K ﹤0.01% 829
2024
Q4
$1.01K Buy
+28
New +$947 ﹤0.01% 879
2023
Q3
– Sell
-24
Closed -$589 – 1090
2023
Q2
$589 Sell
24
-1
-4% -$32 ﹤0.01% 967
2023
Q1
$1.02K Buy
+25
New +$1.03K ﹤0.01% 892
2022
Q4
– Sell
-11
Closed -$1K – 1188
2022
Q3
$1K Sell
11
-12
-52% -$658 ﹤0.01% 927
2022
Q2
$1K Buy
+23
New +$1.89K ﹤0.01% 933

Other funds holding TNDM

Prestige Wealth Management Group's TNDM Position: Q4 2025 in Review

Prestige Wealth Management Group sold out of Tandem Diabetes Care (TNDM) in Q4 2025, closing a stake of 65 shares — an estimated $790 sold.

Prestige Wealth Management Group first reported a position in TNDM in Q2 2022 and held it in 8 quarters. The position peaked at $1.21K in Q2 2025. 269 funds tracked by Wall St. Rank hold TNDM as of Q4 2025.

  • Prestige Wealth Management Group reported no remaining Tandem Diabetes Care position as of Q4 2025 after selling out during the quarter.
  • Prestige Wealth Management Group sold 65 Tandem Diabetes Care shares in Q4 2025, an estimated $790.
  • Prestige Wealth Management Group first reported a position in Tandem Diabetes Care in Q2 2022 and held it in 8 quarters.
  • Prestige Wealth Management Group's Tandem Diabetes Care position peaked at $1.21K in Q2 2025.
  • 269 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2025.

Based on Prestige Wealth Management Group's 13F filing for Q4 2025, filed 11 Feb 2026.